Huntington National Bank Makes New $164,000 Investment in Harrow, Inc. (NASDAQ:HROW)

Huntington National Bank acquired a new position in shares of Harrow, Inc. (NASDAQ:HROW) during the 3rd quarter, HoldingsChannel.com reports. The fund acquired 3,650 shares of the company’s stock, valued at approximately $164,000.

A number of other large investors have also made changes to their positions in HROW. Vanguard Group Inc. increased its stake in Harrow by 1.2% during the first quarter. Vanguard Group Inc. now owns 1,829,805 shares of the company’s stock valued at $24,208,000 after acquiring an additional 21,253 shares during the period. SG Americas Securities LLC bought a new stake in shares of Harrow during the third quarter valued at approximately $534,000. Semanteon Capital Management LP acquired a new position in shares of Harrow in the third quarter valued at $686,000. Private Capital Management LLC lifted its position in Harrow by 7.8% in the first quarter. Private Capital Management LLC now owns 3,012,393 shares of the company’s stock worth $39,854,000 after purchasing an additional 217,896 shares during the period. Finally, Apis Capital Advisors LLC acquired a new stake in Harrow during the second quarter worth $1,660,000. Institutional investors and hedge funds own 72.76% of the company’s stock.

Harrow Trading Down 9.0 %

Shares of Harrow stock opened at $39.01 on Monday. Harrow, Inc. has a 12-month low of $8.01 and a 12-month high of $59.23. The stock has a market capitalization of $1.38 billion, a P/E ratio of -41.50 and a beta of 0.76. The company has a 50-day simple moving average of $47.92 and a 200 day simple moving average of $32.43. The company has a quick ratio of 2.43, a current ratio of 2.60 and a debt-to-equity ratio of 3.18.

Analyst Ratings Changes

A number of research firms have recently commented on HROW. Craig Hallum raised their price objective on shares of Harrow from $45.00 to $65.00 and gave the stock a “buy” rating in a report on Friday, October 4th. B. Riley reaffirmed a “buy” rating and set a $50.00 price objective on shares of Harrow in a report on Thursday, August 29th. Finally, Lake Street Capital upped their price objective on Harrow from $45.00 to $55.00 and gave the company a “buy” rating in a research note on Friday, October 4th.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.